Get started
Author

Allen Knight

Observed name: A. Knight
ORCID: 0000-0001-8123-9547
Observed ORCID: 0000-0001-8123-9547
OpenAlex ID: A5042635558
Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study
2021 · Richard T. Bryan, Wenyu Liu, et al. · European Urology · 63
PDF
CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin‐C vs surgical management in low‐risk non‐muscle‐invasive bladder cancer
2020 · A. Hugh Mostafid, Nuria Porta, et al. · British Journal of Urology · 53
PDF
Developing a Diagnostic Multivariable Prediction Model for Urinary Tract Cancer in Patients Referred with Haematuria: Results from the IDENTIFY Collaborative Study
2022 · Sinan Khadhouri, Kevin M. Gallagher, et al. · European Urology Focus · 32
Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real‐world findings from NHS England between 2013 and 2019
2023 · James W.F. Catto, Olena Mandrik, et al. · British Journal of Urology · 31
PDF
Erratum: Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial
2025 · Richard T. Bryan, Wenyu Liu, et al. · Journal of Clinical Oncology · 18
Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial
2025 · Richard T. Bryan, Wenyu Liu, et al. · Journal of Clinical Oncology · 15
Patient and Carer Experiences with Bladder Cancer: Results from a Global Survey in 45 Countries
2023 · Lydia E. Makaroff, Alex Filicevas, et al. · European Urology · 10
Properties of non-coding mutation hotspots as urinary biomarkers for bladder cancer detection
2023 · L. Baxter, N. S. Gordon, et al. · Scientific Reports · 10
PDF
Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT
2024 · Nicholas James, Sarah Pirrie, et al. · Health Technology Assessment · 8
The bladder cancer patient survey: Global perspectives on awareness and treatment of bladder cancer
2019 · Josephine Elliott, Ranveig Rotterud, et al. · Journal of Cancer Policy · 8
Boosting and broadening recruitment to UK cancer trials: towards a blueprint for action
2023 · Veronica Nanton, Richard T Bryan, et al. · BMJ Oncology · 7
PDF
The experience of UK patients with bladder cancer during the COVID‐19 pandemic: a survey‐based snapshot
2020 · Sarah Spencer‐Bowdage, Beth Russell, et al. · British Journal of Urology · 7
PDF
Replacing TURBT with mpMRI for staging MIBC: Pilot data from the BladderPath study.
2020 · Nicholas D. James, Sarah Pirrie, et al. · Journal of Clinical Oncology · 5
Correction to: Meeting abstracts from the 4th International Clinical Trials Methodology Conference (ICTMC) and the 38th Annual Meeting of the Society for Clinical Trials
2018 · Steven Penegar, Rebecca Lewis, et al. · Trials · 5
PDF
LBA111 Randomized comparison of upfront magnetic resonance imaging versus transurethral resection for staging new bladder cancers: Final survival analysis from the BladderPath trial
2025 · N.D. James, S. Pirrie, et al. · Annals of Oncology · 4
PDF
Use of gene expression patterns to identify unique molecular subtypes in muscle invasive bladder cancer: GUSTO.
2024 · Simon J. Crabb, Syed A. Hussain, et al. · Journal of Clinical Oncology · 3
The experience of UK patients with bladder cancer during the second wave of the COVID‐19 pandemic
2022 · Beth Russell, Sarah Spencer‐Bowdage, et al. · BJUI Compass · 2
PDF
Patient experience of surveillance following radical treatment for muscle‐invasive bladder cancer
2023 · Joanna Hack, James Douglas, et al. · British Journal of Urology · 1
PDF
12 month results of CALIBER: A phase II randomised feasibility trial of chemoablation with MMC versus surgical management in low risk (LR) non-muscle invasive bladder cancer (NMIBC)
2019 · H. Mostafid, N. Porta, et al. · European Urology Supplements · 1
Pd66-04 Results of Caliber: a Phase Ii Randomised Feasibility Trial of Chemoablation Versus Surgical Management in Low Risk Non-muscle Invasive Bladder Cancer (nmibc)
2018 · Hugh Mostafid, Joanne Cresswell, et al. · The Journal of Urology · 1
PDF
Results of CALIBER: A phase II randomised feasibility trial of chemoablation versus surgical management in low risk non-muscle invasive bladder cancer
2018 · H. Mostafid, J. Cresswell, et al. · European Urology Supplements · 1
Acceptability of at-home urine self-testing for bladder health problems: a qualitative study
2026 · Emma Lidington, Ninian Schmeising-Barnes, et al. · BMC Public Health
AURORA: A single arm, multicentre, phase II clinical trial of atezolizumab immunotherapy for advanced squamous cell carcinoma of the bladder and urinary tract.
2025 · Simon J. Crabb, Jonathan Martin, et al. · Journal of Clinical Oncology
PDF
P223 Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA) – a single arm, open-label, multicentre, phase II clinical trial in progress
2024 · M. Lawrence, S. Crabb, et al. · European Urology Open Science
Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA): study protocol for a single arm, open-label, multicentre, phase II clinical trial
2023 · Simon Crabb, Robin Wickens, et al. · BMC Cancer
PDF
Works count: 26
Citation count: 285
H-index: 8
I10-index: 8
Year
Topic
Type